Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors

/PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of...

Related Keywords

Germany ,New York ,United States ,Netherlands ,United Kingdom ,New York University ,Singapore ,Switzerland ,London ,City Of ,Dutch ,Swiss ,Bertrand Damour ,Danny Reinberg ,Michael Gladstone ,Minerva Neurosciences ,Shaun Kirkpatrick ,David Thurston ,Leigh Zawel ,Rogier Rooswinkel ,Jonathan Tobin ,Paul Jackson ,Geneprot Inc ,Novartis Institutes For Biomedical Research ,Biotechnologies At Research Corporation Technologies ,Boehringer Ingelheim ,European Recovery Programme ,Merck Co ,Rabobank International ,Deutsche Bank ,Jp Morgan ,Taiho Pharmaceuticals ,Atlas Venture ,York University School Of Medicine ,Company Board ,Dutch Venture Initiative ,Research Corporation Technologies ,Brandon Capital ,Chief Executive ,Chief Scientific ,Antibody Drug Conjugate ,Executive Officer Bertrand Damour ,Professor David ,Professor Thurston ,Chief Executive Officer ,Pheon Therapeutics ,Cullinan Oncology ,Vice President ,East Coast Site Head ,Therapeutic Innovation ,Oncology Site Head ,Novartis Institutes ,Biomedical Research ,Molecular Pharmacology ,New York University School ,Chief Scientific Officer ,Chair Jonathan Tobin ,General Partner ,President Biotechnologies ,Brandon Biocatalyst ,United Nations Principles ,Kfw Capital ,Venture Capital Fonds ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Personnel Announcements ,Venture Capital ,